Apolipoprotein (apo) A-I is the major apoprotein of plasma high density lipoproteins (HDL). Plasma lipoproteins play pivotal roles in cholesterol metabolism and are important factors for identifying those people at risk for atherosclerosis, stroke and cardiovascular disease. Individuals with high levels of circulating HDL are at lower risk for the complications of atherosclerosis. Numerous functions of apo A-I have been identified that contribute to its beneficial properties. These include the capacity of apo A-I to: 1) activate the enzyme that esterifies cholesterol in plasma, lecithin: cholesterol acyl transferase (LCAT), b) mediate cholesterol delivery to steroidogenic tissues, c) facilitate cholesterol egress from certain nonhepatic peripheral cells such as the cholesteryl ester loaded macrophage (e.g., the foam cells of the atherosclerotic lesion), and d) enhance fibrinolysis. Thus, apo A-I plays an important role in vascular biology and cholesterol metabolism. The primary structure of apo A-I is known, however, specific regions of apo A-I that are responsible for carrying out these functions are largely unknown. Using an immunochemical approach, the relationship between apoprotein structure and function will be explored. Four functions will be studied including LCAT activation, cholesterol delivery to steroidogenic cells, cholesterol unloading from macrophages, and the enhancement of fibrinolysis. An existing panel of apo A-I-specific monoclonal antibodies, which are directed towards unique regions on apo A-I, will be screened for their ability to block each of these apo A-I functions. When antibodies are found that interfere with a particular function, the fragments that represent the functionally important regions of apo A-I will be tested for their ability to either mimic or block apo A-I function. These studies will verify the hypothesis that specific structural regions on apo A-I can be identified that are responsible for each of its many functions. Furthermore, the successful completion of these studies will begin to provide detailed information regarding the specificity mechanism and physiologic importance of the activation of LCAT, cellular interactions, and the enhancement of fibrinolysis by apo A-I.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL043815-04
Application #
3362583
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1990-07-01
Project End
1995-06-30
Budget Start
1993-07-23
Budget End
1994-06-30
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Hime, Neil J; Black, Audrey S; Bulgrien, Josh J et al. (2008) Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP. J Lipid Res 49:2113-23
Valenta, David T; Bulgrien, Joshua J; Bonnet, David J et al. (2008) Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J Lipid Res 49:24-32
Valenta, David T; Bulgrien, Joshua J; Banka, Carole L et al. (2006) Overexpression of human ApoAI transgene provides long-term atheroprotection in LDL receptor-deficient mice. Atherosclerosis 189:255-63
Curtiss, Linda K; Valenta, David T; Hime, Neil J et al. (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26:12-9
Valenta, David T; Ogier, Nicolas; Bradshaw, Gary et al. (2006) Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 26:1572-8
Wiedmer, Therese; Zhao, Ji; Li, Lilin et al. (2004) Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3). Proc Natl Acad Sci U S A 101:13296-301
Binder, Christoph J; Hartvigsen, Karsten; Chang, Mi-Kyung et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114:427-37
Desrumaux, Catherine M; Mak, Puiying A; Boisvert, William A et al. (2003) Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 44:1453-61
Rye, Kerry-Anne; Duong, MyNgan; Psaltis, Maria K et al. (2002) Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. Biochemistry 41:12538-45
Mak, Puiying A; Laffitte, Bryan A; Desrumaux, Catherine et al. (2002) Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 277:31900-8

Showing the most recent 10 out of 26 publications